» Articles » PMID: 39494103

Advancing Diabetes Management: Exploring Pancreatic Beta-cell Restoration's Potential and Challenges

Overview
Specialty Gastroenterology
Date 2024 Nov 4
PMID 39494103
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetes mellitus, characterized by chronic hyperglycemia due to insulin deficiency or resistance, poses a significant global health burden. Central to its pathogenesis is the dysfunction or loss of pancreatic beta cells, which are res-ponsible for insulin production. Recent advances in beta-cell regeneration research offer promising strategies for diabetes treatment, aiming to restore endogenous insulin production and achieve glycemic control. This review explores the physiological basis of beta-cell function, recent scientific advan-cements, and the challenges in translating these findings into clinical applications. It highlights key developments in stem cell therapy, gene editing technologies, and the identification of novel regenerative molecules. Despite the potential, the field faces hurdles such as ensuring the safety and long-term efficacy of regen-erative therapies, ethical concerns around stem cell use, and the complexity of beta-cell differentiation and integration. The review highlights the importance of interdisciplinary collaboration, increased funding, the need for patient-centered approaches and the integration of new treatments into comprehensive care strategies to overcome these challenges. Through continued research and collaboration, beta-cell regeneration holds the potential to revolutionize diabetes care, turning a chronic condition into a manageable or even curable disease.

Citing Articles

Molecular Research on Diabetes.

Puddu A, Maggi D Int J Mol Sci. 2025; 26(5).

PMID: 40076500 PMC: 11899755. DOI: 10.3390/ijms26051873.


Identifying Promising Immunomodulators for Type 1 Diabetes (T1D) and Islet Transplantation.

Ajmal N, Bogart M, Khan P, Max-Harry I, Healy A, Nunemaker C J Diabetes Res. 2024; 2024:5151171.

PMID: 39735417 PMC: 11679277. DOI: 10.1155/jdr/5151171.

References
1.
Song W, Shah R, Hussain M . The use of animal models to study stem cell therapies for diabetes mellitus. ILAR J. 2010; 51(1):74-81. DOI: 10.1093/ilar.51.1.74. View

2.
Hu D, Wang Y, Zhang H, Kong D . Identification of miR-9 as a negative factor of insulin secretion from beta cells. J Physiol Biochem. 2018; 74(2):291-299. DOI: 10.1007/s13105-018-0615-3. View

3.
Koblas T, Leontovyc I, Loukotova S, Kosinova L, Saudek F . Reprogramming of Pancreatic Exocrine Cells AR42J Into Insulin-producing Cells Using mRNAs for Pdx1, Ngn3, and MafA Transcription Factors. Mol Ther Nucleic Acids. 2016; 5:e320. PMC: 5014516. DOI: 10.1038/mtna.2016.33. View

4.
Lavens A, Nobels F, De Block C, Oriot P, Verhaegen A, Chao S . Effect of an Integrated, Multidisciplinary Nationwide Approach to Type 1 Diabetes Care on Metabolic Outcomes: An Observational Real-World Study. Diabetes Technol Ther. 2021; 23(8):565-576. DOI: 10.1089/dia.2021.0003. View

5.
Bugliani M, Mossuto S, Grano F, Suleiman M, Marselli L, Boggi U . Modulation of Autophagy Influences the Function and Survival of Human Pancreatic Beta Cells Under Endoplasmic Reticulum Stress Conditions and in Type 2 Diabetes. Front Endocrinol (Lausanne). 2019; 10:52. PMC: 6399112. DOI: 10.3389/fendo.2019.00052. View